logo
  • Home
  • About
    • Allison Robbins, CFA
  • Services
    • Venture Capital Funds
    • Operating Companies
    • Tech Transfer Offices
    • Pro Bono
  • Media
    • Press
    • White Paper
  • Contact
logo
  • Home
  • About
    • Allison Robbins, CFA
  • Services
    • Venture Capital Funds
    • Operating Companies
    • Tech Transfer Offices
    • Pro Bono
  • Media
    • Press
    • White Paper
  • Contact
Press ReleaseSeptember 30, 2021

Green Shoots Consulting, LLC Co-Sponsors White Paper on Real-World Evidence Ecosystem

Illustration of Digital DNA Framework

An evolution of medical diagnostics, treatments, and services relies upon trusted vendors collectively developing “Digital DNA” – scaled medical datasets, diverse provider networks, and cutting-edge software applications

STUART, Fla., Sept. 30, 2021 /PRNewswire/ — A new white paper co-sponsored by Green Shoots Consulting, LLC offers a unique lens into the emerging confluence of health care subsectors transforming electronic medical records into real-world evidence and medical products and services.

The paper, co-authored by Allison Robbins, CFA of Green Shoots Consulting, LLC, David M. Rubin, PhD of Merck Global Health Innovation Fund, LLC, Junko Saber, MBA of Innopiphany, LLC, and Arash Hanifi, PhD of Merck & Co., Inc., describes the conceptual “Digital DNA” framework to empower health care stakeholders to invest in, partner with, and purchase from health tech companies that have the greatest potential for improving patient care.

“Health IT experts have long envisioned an iterative ‘learning health system’ in which aggregated patient data provides real-time insights that improve care delivery,” said Ms. Robbins. “With the cultivation of Digital DNA, the future of big data supporting patient outcomes is within reach.”

The Digital DNA framework encourages the real-world evidence ecosystem to collectively develop a) high-quality, large-volume “data,” b) scaled, diverse patient and provider “networks,” and c) practical software “applications” to transform real-world data into real-world evidence and medical products and more effectively engage with patients and clinicians.

Discussed life science use cases include the identification and commercialization of novel ‘omics biomarkers, real-world efficacy and safety of pharmaceuticals, and patient and clinician education.

The white paper can be found at medium.com.

About Green Shoots Consulting, LLC

Green Shoots Consulting, LLC, a management and strategy consulting firm, cultivates discovery-stage health care technologies to advance clinical practice, including therapeutics, devices, diagnostics, and software. Clients include corporate and financial venture capital firms, government accelerators, universities, health systems, and health care technology companies.

https://greenshoots.consulting

Contact

Allison Robbins, CFA
Green Shoots Consulting, LLC
[email protected]

SOURCE Green Shoots Consulting, LLC

Related Links

greenshoots.consulting

Previous Cultivating Digital DNA Enables a Thriving Real-World Evidence Ecosystem to Improve Patient Outcomes
Next Verge Genomics Secures $98 Million in New Financing

Related Posts

CD&R, Merck GHI, and McKesson Ventures Invest in Innovative Oncology Data and Informatics Company M2GEN

March 17, 2021

Verge Genomics Secures $98 Million in New Financing

December 16, 2021

Avation Medical raises $22M+ from impressive line-up of new global investors to jump-start sales of the first closed-loop wearable neuromodulation technology for bladder treatment

February 2, 2024

McDermott Represents MERCK GHI in its investment in M2GEN

March 23, 2021
© 2021 Green Shoots Consulting, LLC © 2016 Bateaux Theme All rights reserved